| Address: | 75 Shoreway Rd C, San Carlos, CA 94070, USA |
|---|---|
| Postal code: | 94070 |
| Phone: | (650) 931-6236 |
| Website: | http://www.apexigen.com/ |
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Apexigen, use the form below and your opinion, advice or comment will appear in this space.
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products.
Seven product candidates discovered using APXiMAB™ are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com. Contacts . Apexigen, Inc. Mark Nevins Vice President, Business Development 650-931-6236
Apexigen Inc. company research & investing information. ... 650-931-6236. Fax: 650-931-6235. ... The trial is being funded by Apexigen and is being conducted by researchers at Columbia University ...
Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply. Ingelheim, ... +1 650 931-6236. Home:
863 Mitten Road, Suite 103Burlingame, CA 94010 650-931-6236 www.apexigen.com
Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could ...
Seven product candidates discovered using APXiMAB TM are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com. Apexigen Contact: Mark Nevins Vice President, Business Development 650-931-6236 mnevins@apexigen.com
Seven product candidates discovered using APXiMAB are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com. Apexigen Contact: Mark Nevins Vice President, Business Development 650-931-6236 mnevins@apexigen.com
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors Study to evaluate potential of APX005M plus Opdivo to activate antigen-presenting cells in the tumor microenvironment to demonstrate enhanced anti-tumor activity
Collaboration with Bristol-Myers Squibb, Apexigen will test CD40 antibody APX005M, nivolumab and chemotherapy. SAN FRANCISCO - Sept. 20, 2017 - The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute today announced the first patients have begun treatment in a new pancreatic cancer multi-center clinical trial.